VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$1.88 USD
+0.01 (0.70%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $1.88 0.00 (0.00%) 5:30 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Brokerage Reports
VYNE Therapeutics Inc. [VYNE]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; BETi Platform Shows Signs of Green Shoots; VYN202 Phase 1a Data by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN202 Phase 1a Trial Achieves Lift-Off; Data Expected in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Ready, Set, Go!; First Patient Dosed in VYN201 Phase 2b Vitiligo Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; VYN202 and VYN201 Ready to Take Root With Upcoming Clinical Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Green Shoots in Time for Spring; VYN202 Receives IND Clearance to Kick Off Clinical Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Seeds Are Sown For BETi Pipeline''s Clinical Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biomarker Results Reinforce VYN201''s MoA and Previous Positive Phase 1b Data; Phase 2b to Start in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Buoyed by Positive Initial Data, BETi Pipeline Progresses Through Clinical Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Fruits of Labor; KOL Event Spotlights VYNE''s Recent Clinical Development Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Positive Early Vitiligo Clinical Data and VYN202 Profile Building; Target Reduced to $5.75 on Significant Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; BETi Program Shows Signs of Blossoming; Topline Phase 1b Vitiligo Data in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; BETi Program Continues to Put Down Roots; VYN201 Phase 1b Data in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYNE''s Latest Harvest: VYN202 Joins the InhiBET Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201 Takes Root in Preclinical Model of IPF
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201''s Safety Profile Matures on the Vine; Top-Line Phase 1b Vitiligo Data in Mid-23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Project Strong BETi Visibility This Year; Favorable Safety a Great Start; Split-Adjusted Target to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201 Continues to Bloom As First Vitiligo Patient Dosed in Phase 1a/b trial; Top-Line Data Expected 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Start of Phase 1a/b Sows the Seeds for VYN201''s Future Clinical Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Ready, Set, Go!; VYN201 About to Initiate Phase1 Vitiligo Trial in the Coming Weeks
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; BETi Program Readies For a Turn at Bat; Phase 1a/b in Vitiligo Slated to Begin in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J